Table of Contents
I. Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
II. Upcoming NIH virtual events on data analysis and interpretation
III. Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)
IV. Notice to Add a Receipt Date to RFA-DA-21-019 “Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)”
V. Notice of Change to RFA-DA-21-005 "Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)"
VI. Biomedical Data Repository (U24 – Clinical Trials Not Allowed) – PAR-20-089
VII. Biomedical Knowledgebase (U24 – Clinical Trials Not Allowed) – PAR-20-097
I.Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html
This is an unique “emergency” solicitation to develop the surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions with a high density of individuals who are together for prolonged periods of time. The timeline for award is extremely fast, with earliest starting date in November 2020, in just four months.
Please see below the description of NIDA interest:
National institute on Drug Abuse (NIDA)
NIDA has previously supported several surveillance technologies initially intended for drug and overdose detection that could be amenable for real-time, spatially selective, early detection of COVID-19. NIDA is interested in adapting the technologies to the current needs of the communities struggling with the substance use disorders (SUD) that are disproportionally affected by COVID-19, including residents of in-patient SUD treatment facilities. Despite the recent favorable changes in some policies related to the outpatient vs. inpatient treatment options, for many SUD patients the outpatient measures are not considered an adequate clinical option (e.g. life-threatening situations for people at high risk for overdose or complications from withdrawal). Inpatient/residential programs that need to remain open during the current COVID-19 related emergency have been advised to follow the Centers for Disease Control and Prevention guidance on precautions in admitting new patients, management of current residents who may have been exposed to or who are infected with COVID-19, and visitor policies. NIDA is particularly interested in surveillance platforms that would specifically address the needs of the SUD inpatient/residential programs with the focus on admitting new patients during the pandemic and providing uninterrupted services to the current residents.
Please contact:
Elena Koustova; Elena.koustova@nih.gov; 301-496-8768
------------
II. Upcoming NIH virtual events on data analysis and interpretation:
- Adolescent Brain Cognitive Development (ABCD) Study – ReproNim Virtual Course October – February, 2021. The ABCD-ReproNim Course provides a comprehensive background to data from the ABCD Study® while delivering hands-on, interactive instruction to enable rigorous and reproducible data analyses (see attached flyer). The course runs from October – February and is targeted to students, postdocs, and early career faculty. Visit the ABCD-ReproNim website for more information and to apply.
- Beyond Statistical Significance: Understanding Meaningful Effects Virtual Workshop September 2. An inherent consequence of large, observational studies is that although effects may be statistically significant, they may only account for a small proportion of the variance. The objective of this workshop is to develop best practice recommendations for interpreting effects in “big data” by engaging scientists from a range of disciplines in discussions of meaningful science that go beyond statistical significance. Visit the meaningful effects meeting website for more information and to register.
For more information contact
Elizabeth A. Hoffman, Ph.D.
Scientific Program Manager, Adolescent Brain Cognitive Development (ABCD) Study
Division of Extramural Research
National Institute on Drug Abuse, NIH
6001 Executive Blvd. Room 4245
Bethesda, MD 20892-9550
Email: elizabeth.hoffman@nih.gov
Office: 301-594-2265
Cell: 240-461-3684
III.Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)
https://grants.nih.gov/grants/guide/pa-files/PAR-20-182.html
Due date: October 30, 2020
NIDA intends to commit $2M in FY2021 to fund 1-3 awards.
IV. Notice to Add a Receipt Date to RFA-DA-21-019 “Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)”
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-019.html
Due date: July 2021
NIDA intends to commit $4M in FY2022 to fund 1-4 applications
V. Notice of Change to RFA-DA-21-005 "Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)"
https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-056.html
Due Date: August 2021
NIDA intends to commit $3M in FY2022 to fund 5-8 awards.
VI. Biomedical Data Repository (U24 – Clinical Trials Not Allowed) – PAR-20-089
https://grants.nih.gov/grants/guide/pa-files/PAR-20-089.html
Earliest Submission Date: August 25, 2020
Purpose: This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of the community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase. Applications that have a significant focus on software or tool development are not appropriate for this activity.
VII. Biomedical Knowledgebase (U24 – Clinical Trials Not Allowed) – PAR-20-097
https://grants.nih.gov/grants/guide/pa-files/PAR-20-097.html
Earliest Submission Date: August 25, 2020
Purpose: This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment